clinical biopharmaceutical News
-
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’s previously announced share repurchase program. Under the now suspended share repurchase program, the Company repurchased approximately 520,000 shares of common stock for ...
-
Altimmune to Present at Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment Conference Tuesday, May 24, 2022 7:00 am Eastern Time The session will be webcast and can be accessed by visiting the Events section of the Altimmune ...
-
Enterome to present the significant potential of its Mimicry concept, platform and pipeline at BMO’s Biopharma Spotlight Series conference – Immunology and Inflammation
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial effector-based drug discovery platform, announces that its CEO, Pierre Belichard, will present at the BMO Biopharma Spotlight Series conference on Immunology and Inflammation, which will take place virtually April 6, 2022. ...
By Enterome
-
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022: Jefferies 2022 Global Healthcare Conference in New York, NY Friday, June 10, 2022 Fireside chat at 10:00 am Eastern Time JMP Securities Life Sciences Conference in New York, NY ...
-
Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference
OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, and Georgy Egorov, Chief Financial Officer, are participating at the 33rd Annual Virtual Piper Sandler Healthcare Conference ...
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
New York, New York, March 22, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan Horsager, Ph.D., President and Chief Executive Officer of Duet BioTherapeutics, will present at the 3rd Annual STING & TLR-Targeting ...
-
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Mark Guerin, Chief Operating Officer & Chief Financial Officer, will ...
-
Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based ...
-
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. As previously announced, the Phase III clinical trial was placed on clinical hold by the FDA ...
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the results of the Company's recently completed Phase 1 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH, will be presented in an oral presentation at the 82nd American Diabetes Association (ADA) Scientific ...
-
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10th at 7:00 a.m. Eastern Time. The virtual session may be accessed on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The ...
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under ...
-
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
April 22, 2022 at 8:00 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 22, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview with ...
-
Axial Biotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that management will present at the H.C. Wainwright Annual Global Investment Conference on Tuesday, September 15, 2020 at 2:00 PM ET. About Axial Biotherapeutics Axial Biotherapeutics is a clinical stage ...
-
Axial Therapeutics to Participate in a Fireside Chat Hosted by LifeSci Capital
Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will participate in a fireside chat hosted by LifeSci Capital on Tuesday, November 17, 2020 at 1:00 PM ET. About Axial Therapeutics Axial Therapeutics is a clinical-stage, ...
-
Onconova Therapeutics Announces Acceptance Of Abstract For Publication At The ASCO Annual Meeting
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting. Details on the abstract are provided below. Abstract Title: Narazaciclib’s kinase inhibitory ...
-
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
BASKING RIDGE, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Independent Data Monitoring Committee (“IDMC”) overseeing the Phase 1b, ...
-
Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market
New York, New York, November 22, 2021 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it has entered into securities purchase agreements with certain institutional investors in connection with a private placement priced ...
-
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: ...
By Lumos Pharma
-
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised ...
By IN8Bio Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you